Anti-Viral Surfaces in the Fight against the Spread of Coronaviruses

Membranes, Journal Year: 2023, Volume and Issue: 13(5), P. 464 - 464

Published: April 27, 2023

This review is conducted against the background of nanotechnology, which provides us with a chance to effectively combat spread coronaviruses, and primarily concerns polyelectrolytes their usability for obtaining protective function viruses as carriers anti-viral agents, vaccine adjuvants, and, in particular, direct activity. covers nanomembranes form nano-coatings or nanoparticles built natural synthetic polyelectrolytes--either alone else nanocomposites creating an interface viruses. There are not wide variety activity SARS-CoV-2, but materials that effective virucidal evaluations HIV, SARS-CoV, MERS-CoV taken into account potentially active SARS-CoV-2. Developing new approaches interfaces will continue be relevant future.

Language: Английский

---

Plant‐derived compounds as potential leads for new drug development targeting COVID‐19

Phytotherapy Research, Journal Year: 2024, Volume and Issue: 38(3), P. 1522 - 1554

Published: Jan. 28, 2024

Abstract COVID‐19, which was first identified in 2019 Wuhan, China, is a respiratory illness caused by virus called severe acute syndrome coronavirus 2 (SARS‐CoV‐2). Although some patients infected with COVID‐19 can remain asymptomatic, most experience range of symptoms that be mild to severe. Common include fever, cough, shortness breath, fatigue, loss taste or smell and muscle aches. In cases, complications arise including pneumonia, distress syndrome, organ failure even death, particularly older adults individuals underlying health conditions. Treatments for remdesivir, has been authorised emergency use countries, dexamethasone, corticosteroid used reduce inflammation cases. Biological drugs monoclonal antibodies, such as casirivimab imdevimab, have also certain situations. While these treatments improved the outcome many patients, there still an urgent need new treatments. Medicinal plants long served valuable source drug leads may serve resource development due their broad‐spectrum antiviral activity. To date, various medicinal plant extracts studied cellular molecular interactions, demonstrating anti‐SARS‐CoV‐2 activity vitro. This review explores evaluation potential therapeutic applications against SARS‐CoV‐2. summarises latest evidence on different isolated bioactive compounds SARS‐CoV‐2, focus application plant‐derived animal models human studies.

Language: Английский

---

The importance of booster vaccination in the context of Omicron wave

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Sept. 8, 2022

Omicron (B.1.1.529) was first detected in a sample collected Botswana on November 11, 2021, and has rapidly replaced Delta as the dominant global variant given robust transmissibility. Moreover, it displays lower virulence than other variants. However, pathogenicity of appears to be underestimated view increasing levels herd immunity through natural infection or vaccination. Additionally, volume hospitalizations deaths increase proportion number cases due high transmissibility Omicron. Therefore, vaccination remains an important public health priority. Notably, series mutations spike protein, especially receptor-binding domain N-terminal domain, associated with immune escape capacity, reducing willingness people receive vaccines. Herein, we provide in-depth discussion assess effectiveness second third against variant. On one hand, two-dose program adopted by many countries is insufficient prevent correlated decline vaccine efficacy over time. booster dose significantly increases protective infection. Most importantly, heterologous induces more response homologous dose. under special background this pandemic, there urgent need accelerate vaccination, providing better strategies, combat emerging

Language: Английский

---

Could the New BA.2.75 Sub-Variant Cause the Emergence of a Global Epidemic of COVID-19? A Scoping Review

Infection and Drug Resistance, Journal Year: 2022, Volume and Issue: Volume 15, P. 6317 - 6330

Published: Oct. 1, 2022

Abstract: With over 58 million cases and 6 deaths by August 2022, the Coronavirus disease 2019 (COVID-19), causing severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2), has had an insurmountable impact on world's population. This is one of worst health crises since 1918's influenza pandemic. There are four subvariants Omicron; BA.1, BA.1.1, BA.2 BA.3. As a result new mutations in its spike protein, most which occur receptor binding site, Omicron variant appears to be more transmissible less resistant vaccination antibody response. Understanding Omicron's virology essential developing diagnostic therapeutic methods. A thorough assessment control measures, as well timely adjustment requires addressing such issues re-infection risk, vaccine response, booster doses, increased rate infections. review article aims look at current information about different types SARs-CoV-2, focusing subtype BA.2.75. Keywords: outbreak, Omicron, subvariant, BA.2.75, COVID-19

Language: Английский

---

Age and Sex Differences Among Mildly Symptomatic and Asymptomatic Patients with Omicron Infection in 2022 in Shanghai, China

Journal of Multidisciplinary Healthcare, Journal Year: 2022, Volume and Issue: Volume 15, P. 1909 - 1919

Published: Aug. 1, 2022

An epidemic of the Omicron variant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in March 2022, and over 600,000 cases were confirmed until early May 2022 Shanghai, China. Data on infections are available other countries, but clinical features patients Chinese population, especially still lacking. We collected data from a subset asymptomatic mildly ill to learn about age sex disparity infection based changes cycle threshold values.The basic information 325 who consecutively admitted Shanghai Geriatrics Center was through medical records, tested for viral nucleic acid carriage using nasal swab samples during hospitalization. SAS 9.4 used analysis, p value < 0.05% considered statistically significant.Among included patients, 58.8% males, with mean 47.2 years 13.6 days hospitalization average. The average number tests among female 4.7, which higher than that male (4.1). median slope (Ct) detection (NAD) test 1.4. Logistic regression indicated proportion Ct >1.5 slightly (odds ratio (OR) = 1.06, 95% confidence interval (CI): 0.68-1.66), aged <45 45-59 had ≥60 years. values more variable stages stabilized later infection.Among mild illness or infection, is good, timely, cost-effective method reflect recovery progress patients. steeper younger indicates faster disease recovery.

Language: Английский

---